Evotec's Partner Bayer Starts Mid-stage Study of Genetic Kidney Disease Drug

04:33 AM EST, 12/04/2025 (MT Newswires) -- Evotec (EVT.F) said Thursday its partner Bayer (BAYN.F) commenced a phase 2a study of BAY 3401016, a potential treatment for rare genetic kidney disease Alport syndrome. The clinical trial called Assess will evaluate the efficacy and safety of the monoclonal antibody in patients between the ages of 18 and 45. Once the first patient is dosed in early 2026, Evotec will receive a milestone payment, in line with the companies' 2016 collaboration deal. It also includes additional development and sales milestone payments, alongside royalties.